Tests shorter-course radiation after surgery for cervical cancer
Tests a shorter radiation schedule after surgery in adults with cervical cancer.
Plain-language title generated from the registry record
Registry title: Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Cervical Cancer
Key facts
- Where
- Beijing and Langfang, ChinaSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 75 years old?
Source: NCT07684508, who can take part
Where in China
- Cancer Hospital, Chinese Academy of Medical SciencesBeijing, ChinaTaking people
- Lang Fang Campus of Cancer Hospital, Chinese Academy of Medical SciencesLangfang, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Manni Huang
- Trial code
- NCT07684508
- Record updated
- 5 August 2026
- Original description
To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancerRead full original descriptionShow less
Adjuvant Moderately Hypofractionated Intensity-modulated Radiotherapy for Postoperative Cervical Cancer (AMICA-CC) : a Prospective, Multicenter, Phase II Trial
To investigate the safety and efficacy of moderately hypofractionated intensity-modulated radiotherapy in the treatment of postoperative cervical cancer
Inclusion: ECOG performance status 0 or 1; Histologically confirmed cervical squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma; Status post radical hysterectomy with pelvic lymph node dissection with or without para-aortic lymph node dissection, and postoperative radiotherapy initiated within 3 months; For squamous cell carcinoma: meeting Sedlis criteria; for adenocarcinoma and adenosquamous carcinoma: meeting the "four-factor model"; Bone marrow function: white blood cell (WBC) count ≥3.0×10⁹/L, neutrophil count (NEUT) ≥1.5×10⁹/L, platelet count (PLT) ≥80×10⁹/L, hemoglobin (Hb) ≥90 g/L; renal function: normal or serum creatinine (SCr) ≤1.5×upper limit of normal (ULN) or creatinine clearance ≥50 ml/min; hepatic function: total bilirubin (TBIL) ≤1.5×ULN, aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤2.5×ULN; Voluntarily signed the informed consent form prior to study enrollment.
Exclusion: History of active malignant tumor within 3 years prior to initial treatment（except for the cervical cancer）and any locally curable tumors treated with radical therapy; Any high-risk factor confirmed by postoperative pathology: positive lymph node metastasis, positive parametrial invasion, or positive resection margin; History of neoadjuvant therapy prior to enrollment; Local recurrence or distant metastasis prior to enrollment; Severe cardiac, cerebral, hepatic, or renal disorders; Any other conditions deemed unsuitable for this trial by the investigator; Postoperative intestinal obstruction or intestinal adhesion; Long-term immunocompromised state; Pregnant or lactating females; Premature discontinuation of treatment for any reason; Poor compliance, unwillingness to participate, or inability to cooperate with follow-up.